SSRIs and delayed orgasm
Last reviewed 03/2023
- selective serotonin reuptake inhibitors (SSRIs) are a common cause of drug-induced
hyperprolactinaemia
- SSRIs are associated with an approximate eight-fold increased risk of
development of galactorrhoea compared with other antidepressants
- SSRIs are associated with an approximate eight-fold increased risk of
development of galactorrhoea compared with other antidepressants
- also delayed orgasm or ejaculation is a possible adverse effect in men treated with SSRIs
- monoamine oxidase inhibitors and tricyclic antidepressants have also been rarely reported to cause galactorrhoea or hyperprolactinaemia
Sexual dysfunction and SSRIs
- sexual dysfunction occurs through several brain pathways involving increases
in serotonin (5-HT), decreases in dopamine (DA) and inhibition of nitric oxide
synthase
- increases in cortico-limbic 5-HT result in decreased sexual desire,
ejaculation and orgasm selective serotonin reuptake inhibitor (SSRI)-induced
sexual dysfunction occurs in 30%-80% of patients and is a main cause of
treatment discontinuation
- increases in cortico-limbic 5-HT result in decreased sexual desire,
ejaculation and orgasm selective serotonin reuptake inhibitor (SSRI)-induced
sexual dysfunction occurs in 30%-80% of patients and is a main cause of
treatment discontinuation
- management
- check PRL - SSRIs can cause drug-induced hyperprolactinaemia
- seek expert advice
- pharmacologic methods to reduce sexual dysfunction involve dose reduction,
augmentation, or switching medication
- since dose reduction is the least disruptive strategy it should
be considered first, particularly in a responder (1)
- altering 5-HT receptor antagonism and agonism can have favourable
sexual effects, but may cause other adverse event
- mirtazapine antagonizes 5-HT2 and 5-HT3 receptors and it has
been successfully used as an add-on therapy for antidepressant-induced
sexual dysfunction
- however associated with a relatively high rate of weight gain
- other possible augmentation therapies that have been used include
cyproheptidine and buspirone
- mirtazapine antagonizes 5-HT2 and 5-HT3 receptors and it has
been successfully used as an add-on therapy for antidepressant-induced
sexual dysfunction
- phospho-diesterase inhibitors e.g. sildenafil have demonstrated
evidence for the reversal of SSRI-induced sexual side effects in men
- DA release enhances sexual function
- evidence supports adjunctive bupropion XL for reversing SSRI-induced
sexual dysfunction in men and women across the domains of desire,
arousal and orgasm
- evidence supports adjunctive bupropion XL for reversing SSRI-induced
sexual dysfunction in men and women across the domains of desire,
arousal and orgasm
- several antidepressants, including bupropion, moclobemide, and mirtazapine
have little to no effect on sexual function compared with placebo
when used as a monotherapy
- evidence suggests exercise can improve sexual function in SSRI-induced sexual dysfunction
- since dose reduction is the least disruptive strategy it should
be considered first, particularly in a responder (1)
- check PRL - SSRIs can cause drug-induced hyperprolactinaemia
Reference:
- Rizvi SJ1, Kennedy SH.Management strategies for SSRI-induced sexual dysfunction. J Psychiatry Neurosci. 2013 Sep;38(5):E27-8.